For the Quarter Ending June 2025
North America
• The Price Index of Amphotericin B in the USA declined by 6.66% in April 2025 due to frontloaded imports, tariff uncertainty, and a build-up in supplier inventories.
• The most significant price decrease occurred in April, driven by subdued demand and buyers reducing procurement amidst excess stock and trade ambiguity.
• The Amphotericin B Spot Price continued to soften in May, slipping by 0.31%, as regulatory changes and cautious buyer sentiment restricted fresh orders.
• A temporary easing of U.S.–China trade tensions in mid-May created only marginal impact, with importers still limiting purchase volumes due to tariff volatility.
• May's Demand Outlook was muted as buyers awaited clarity on pricing reforms introduced by a new executive order linking U.S. drug prices to global benchmarks.
• In June, the Price Index rose slightly by 0.20%, supported by anticipatory buying and forward shipments by importers during the extended trade truce.
• June saw steady domestic demand as pharmaceutical firms advanced procurement to secure inventory before further cost surges.
• The Amphotericin B Production Cost Trend reflected mild inflationary pressures, leading buyers to hedge against expected Q3 increases.
• Strategic stockpiling during the quarter helped stabilize prices, despite an overall cautious procurement strategy.
• The Amphotericin B Price Forecast for early Q3 suggests marginal increases due to inventory tightening and unresolved trade policy risks.
China
• The Price Index for Amphotericin B in China fell consistently through April and May before a marginal recovery in June, with Spot Prices at USD 645,000/MT (April), USD 643,000/MT (May), and USD 644,200/MT (June).
• In April 2025, the most significant price drop of -6.66% was recorded due to weak domestic consumption, sluggish global orders, and mounting inventories amid port congestion and U.S. tariff impositions.
• A declining Product Demand Outlook was evident in April, especially from U.S. buyers who canceled or delayed shipments due to a steep 145% tariff.
• China's manufacturing PMI dropped to 49.0 in April, reflecting the worst contraction in over a year, affecting Product Production Cost Trend and factory outputs.
• In May, the Price Index continued to fall by -0.31%, driven by order stagnation, rising inventory levels, and cautious global procurement activity.
• Exporters lowered prices in May to ease backlogs, facing declining new export orders despite a brief tariff relief mid-month.
• The extended Labor Day holiday in May further weakened activity, limiting short-term demand recovery.
• June 2025 saw a slight Price Index rebound of +0.19%, supported by a temporary export surge after a 90-day U.S. tariff suspension.
• Shipping lines raised freight rates from June 1, prompting advanced ordering and enabling suppliers to lift Spot Prices modestly.
• Despite gains in June, uncertainty remains around long-term Amphotericin B Price Forecast, as tariff volatility and cautious production adjustments persist.
Germany
• In April 2025, the Amphotericin B Price Index in Germany declined sharply by 6.66%, primarily due to a supply glut caused by the diversion of US-bound shipments into Europe after the imposition of tariffs by the U.S., saturating the German market with surplus inventory.
• The most significant price drop occurred in April as European buyers had pre-stocked inventories ahead of the Labour Day holiday (May 1–5). This early stocking, combined with weak demand and a lack of new cargo intake, drove down the Product Spot Price significantly.
• Throughout April, imports from Asia and ample shipping capacity ensured continuous supply, maintaining an oversupplied market. Buyers refrained from additional purchases, resulting in a persistently low Product Demand Outlook.
• In May 2025, the Price Index fell further by 0.31%, sustained by high inventory levels and weak retail activity under inflationary pressures. Buyers postponed orders due to logistical uncertainties and a cautious procurement stance.
• The downtrend in May was mainly influenced by post-tariff realignments that rerouted Chinese pharmaceutical cargoes to Europe. This extended oversupply, forcing suppliers to adopt competitive pricing strategies to clear stock.
• May’s inland logistics were further disrupted by worsening port congestion at major hubs like Hamburg and Rotterdam. Despite these challenges, upstream availability remained high, reducing any significant Product Price Forecast recovery.
• In June 2025, the trend reversed slightly with a 0.19% increase in the Price Index, driven by worsening port congestion and Rhine River disruptions, which delayed inbound shipments and prompted early restocking.
• The June price increase was primarily due to tightening supply chains, with importers reacting to prolonged shipping delays by ordering in advance, creating temporary Product Production Cost Trend pressures due to logistical rerouting.
• Despite easing inflation (2% in June), downstream buyers such as pharmacies and hospitals maintained cautious inventory policies. The Product Demand Outlook remained stable but subdued, contributing to a modest pricing uptick.
• Over Q2 2025, Germany’s Amphotericin B market experienced a net negative Price Index trend, with the April glut being the primary deflationary driver, while logistical constraints in June partially stabilized the market.
For the Quarter Ending March 2025
North America
Amphotericin B prices in the USA declined consistently throughout Q1 2025, driven by a convergence of economic headwinds, seasonal disruptions, and geopolitical uncertainties. In January, weakening consumer confidence and severe winter storms slowed downstream pharmaceutical demand and hampered logistics, while preemptive stockpiling—driven by tariff concerns and seasonal procurement—led to an oversupplied market.
February saw further price declines as post-holiday production recovery in China increased export availability, while lower transpacific freight costs sustained inbound supply. However, soft demand persisted amid economic caution, inflation concerns, and delays in ordering due to tariff anxieties.
By March, market conditions worsened as elevated inventories, restrained purchases, and President Trump’s tariff hike on Chinese imports—plus threats against Indian pharmaceuticals—amplified uncertainty. The weakened U.S. dollar added cost pressure to imports, discouraging restocking. As a result, sellers resorted to aggressive price cuts to offload surplus stock.
Throughout the quarter, market sentiment remained subdued with no strong recovery in demand, leading to sustained downward pricing momentum.
Asia Pacific
Amphotericin B prices in China showed a modest rise in January but declined through February and March, resulting in an overall downward trend for Q1 2025. January’s slight increase was driven by steady demand from pharmaceutical and healthcare sectors, limited production ahead of the Lunar New Year, and advance orders amid tariff concerns. However, prices began to fall in February as manufacturers resumed operations post-holiday, boosting output and leading to ample supply. Weak domestic demand, combined with reduced export competitiveness due to U.S. tariffs and a stronger yuan, contributed to growing inventories. The economic environment further dampened buying sentiment, with deflationary pressures and sluggish downstream activity discouraging procurement. In March, production remained strong as firms prepared for summer maintenance, while continued inventory buildup prompted suppliers to offer discounts to stimulate sales. Buyers, having stocked up earlier, delayed fresh orders amid ongoing trade uncertainties and weak foreign interest. Overall, despite early quarter stability, persistent supply-demand imbalance, tariff-related challenges, and muted market activity led to a net decrease in Amphotericin B prices in China during Q1 2025.
Europe
In Q1 2025, Amphotericin B prices in Germany declined consistently due to persistent market imbalances. January marked the beginning of this downward trend, driven by deteriorating consumer sentiment, inflationary pressures, and political uncertainty ahead of national elections. These factors reduced healthcare and pharmaceutical spending, weakening demand. The prospect of U.S. tariffs on Chinese goods prompted Chinese sellers to target Europe, further heightening competition and pressuring prices. In February, the decline continued amid ample supply and subdued demand. The appreciating Euro, along with a steep fall in ocean freight rates on Asia-Europe routes, supported cost-effective imports, resulting in inventory buildup. Early stockpiling ahead of the Lunar New Year kept the market oversupplied. In March, these conditions persisted, with oversupply exacerbated by favorable import economics and healthy shipping capacity. Demand remained muted as buyers prioritized inventory clearance. Despite some port congestion in Europe, falling freight rates and a strong Euro kept landed costs low, reinforcing the soft pricing environment. Throughout Q1, weak domestic sentiment and cautious procurement strategies sustained the downward pressure on Amphotericin B prices in the German market.
For the Quarter Ending December 2024
North America
In Q4 2024, the U.S. Amphotericin B market experienced notable price fluctuations due to a combination of economic conditions and market developments. October saw a decline in prices, largely driven by economic uncertainty, inflation concerns, and weakened consumer demand. A cautious approach from both businesses and consumers, along with external disruptions like hurricanes and strikes, prompted suppliers to lower prices to stimulate sales.
In November, the decline slowed to a minor decrease, as demand continued to soften. A reduction in inflationary pressures and the appreciation of the U.S. dollar helped make imports more affordable. With supply chain issues resolving and inventories remaining well-stocked, prices stabilized and remained relatively steady through the month.
By December, prices began to rise again, fueled by strong demand, proactive purchasing, and the easing of interest rates, which boosted consumer confidence. Anticipation of potential supply disruptions, including strikes and tariffs on Chinese imports, led to increased stockpiling, further driving prices higher as businesses prepared for future cost increases. By the end of the quarter, Amphotericin B was priced at USD 765,000 per metric ton CFR Houston.
Asia Pacific
During Q4 2024, Amphotericin B prices in China experienced fluctuating patterns, influenced by a mix of domestic and global factors. In October, prices saw a slight dip, largely driven by weak domestic demand and an oversupply of stock. Increased competition among suppliers added to the pressure, while geopolitical uncertainties, particularly surrounding the U.S. elections and rising protectionism, suppressed international demand and further contributed to the price decline. The trend persisted into November, with sluggish domestic consumption, high distributor inventories, and a downturn in global sales weighing on prices. Additionally, concerns about impending tariffs fueled uncertainty, keeping the market on edge and preventing any significant recovery. However, December brought a shift as prices began to rise. Strong demand in the pharmaceutical and healthcare sectors, coupled with proactive inventory accumulation ahead of the Chinese Lunar New Year, gave the market a boost. A weaker yuan also made Chinese exports more competitive, further stimulating demand. By the end of Q4, Amphotericin B was priced at USD 733000 per metric ton in China. The quarter's price movement highlighted the market's sensitivity to both domestic demand shifts and international trade dynamics.
Europe
In Q4 2024, Amphotericin B prices in Germany experienced a mix of fluctuations, shaped by a variety of economic and logistical influences. October saw a price decrease, driven by weaker consumer demand amid inflation concerns and a significant reduction in shipping costs, with container prices on Asia-Europe routes dropping by 60%. Businesses adapted by adjusting their logistics strategies, which helped maintain a steady supply, supporting price stability. By November, the market showed signs of stabilization, with only a minor decline in prices. The lingering effects of weak demand and the easing of inflation concerns were still evident, but Germany's economic slowdown and a 1.9% drop in energy costs kept prices in check. Suppliers with well-stocked inventories were able to offer competitive rates, preventing any major shifts in pricing. December brought a reversal, with prices rising due to increased demand from key sectors and logistical challenges ahead of the Chinese Lunar New Year. The weakening Euro and port congestion in Europe further strained supply chains, adding upward pressure on prices. By the end of Q4, Amphotericin B was priced at USD 766,000 per metric ton CFR Hamburg.
For the Quarter Ending December 2022
North America
During the fourth quarter of 2022, Amphotericin B market dynamics fluctuated in the North American region. Prices were expected to increase starting in Q4 2022 and continuing through the second month of the quarter as a result of a high cost of manufacturing, numerous logistical issues, and rising inflation.
Rising transportation costs and port congestion at the key ports also helped to keep the market position strong. A slowdown in API output, disorganization, and rising energy prices all had a positive effect on the market. Due to easing inflation and reducing end-user sector demand, prices started to decline later in December 2022. Values were accessed at USD 6265400/MT CFR Houston at the end of Q4 with an average quarterly inclination of 0.40%.
APAC
During the fourth quarter of 2022, the Amphotericin B market in the Asia-Pacific region showed a general downward trend. Amphotericin B costs have decreased quarterly due to reduced demand from the terminal pharmaceutical sector. An economy that was slowing down, plentiful supplies, and plenty of stocks supported this consistent pricing pattern. Later in December, prices significantly dropped as a result of a dip in domestic and international market inquiries brought on by the approaching holiday and festive season. The market was also impacted by sufficient supply and inventory levels. Towards the termination of Q4 2022, the values accessed at USD 6150500/MT with a quarterly declination of 0.15%.
Europe
In the European market, Amphotericin B prices followed an uptrend in the fourth Quarter of 2022 amidst soaring energy coast and squeezed manufacturing profit margins. Values were accessed at USD 6383940/MT at the end of Q4 2022, with an average quarterly incline of 0.61%. Inflation in the eurozone was recorded to reach a new high of 10.7% in October from 9.6% recorded in September. The price of natural gas for household consumers soared, influencing the market situation. Also, increased production costs kept the market sentiments robust. Later, from the second month of Q4, the prices were witnessed to follow the stable trajectory on the stable back demand from the end-user sector and enough inventories among the domestic merchants.
FAQ
1. Why did the Amphotericin B Price Index decline significantly in April 2025 in North America?
The Price Index dropped by 6.66% in April due to frontloaded imports, tariff uncertainty, and excess inventories built up by suppliers amid a weak demand environment.
2. What caused the continued price softness in May 2025?
In May, the Spot Price slipped by 0.31% as regulatory reforms and buyer hesitation—especially surrounding a new executive order on global pricing benchmarks—restricted fresh procurement.
3. Was there any price recovery observed in June 2025?
Yes, June saw a 0.20% increase in the Price Index, mainly due to anticipatory buying and forward shipments as importers acted on a temporary trade truce between the U.S. and China.
4. What is the Price Forecast for Amphotericin B in early Q3 2025?
The forecast indicates marginal price increases, driven by inventory tightening and unresolved trade policy risks, suggesting a cautiously bullish trend ahead.
